Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?

Detalles Bibliográficos
Autor principal: Schwarzschild, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302030/
https://www.ncbi.nlm.nih.gov/pubmed/28035939
http://dx.doi.org/10.3233/JPD-160975
_version_ 1782506466865840128
author Schwarzschild, Michael A.
author_facet Schwarzschild, Michael A.
author_sort Schwarzschild, Michael A.
collection PubMed
description
format Online
Article
Text
id pubmed-5302030
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-53020302017-02-28 Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects? Schwarzschild, Michael A. J Parkinsons Dis Commentary IOS Press 2017-02-07 /pmc/articles/PMC5302030/ /pubmed/28035939 http://dx.doi.org/10.3233/JPD-160975 Text en IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Schwarzschild, Michael A.
Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
title Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
title_full Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
title_fullStr Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
title_full_unstemmed Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
title_short Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
title_sort could mao-b inhibitor withdrawal rather than nilotinib benefit explain the dopamine metabolite increase in parkinsonian study subjects?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302030/
https://www.ncbi.nlm.nih.gov/pubmed/28035939
http://dx.doi.org/10.3233/JPD-160975
work_keys_str_mv AT schwarzschildmichaela couldmaobinhibitorwithdrawalratherthannilotinibbenefitexplainthedopaminemetaboliteincreaseinparkinsonianstudysubjects

Ejemplares similares